Lists built to your ICP, with the signal that says why now.

Free sample →

Biotech and pharmaceutical companies

2,690 companies in the market · 596+ named decision-makers ready in 24-48 hours · Sized November 2026

Timing signal for this market

Companies that started a new clinical trial in the last 12 months (ClinicalTrials.gov).

In the signal list, every row carries the event, its date and its public source, so you know which companies to contact first. How we build lists

Signals you can ask for

The Signal file comes with the signal above, or choose the one that fits your offer from this list. Each row then shows the signal, its date where it has one, and where it came from.

  • Exhibiting at a trade show in the next 6 months
  • New certification or registration in the last 12 months, from the registry this list is built on
  • Bought, merged or recapitalized in the last 12 months
  • New products or a new facility announced on its own site in the last 6 months
  • Hiring now: open roles on its own site

ClinicalTrials.gov lists 5,291 companies worldwide that sponsored a drug or biologic trial started since 2021 or still open, pulled November 16, 2026. At the rate found in a random 80 checked by hand, about 1,590 are US-headquartered developers still operating, and about 1,100 more US companies, mostly preclinical, have no trial since 2021: about 2,690 in all. A decision-maker can be found for about 8 in 10.

Public, venture-backed and parent-owned companies are all included, each row flagged. A national order delivers 1,000+ companies within 24-48 hours, each with a company phone; the Researched file names a CEO, science, clinical, business development or CMC leader with a verified email at 590+. The Signal file marks the 220+ that started a new trial in the last 12 months. A state or metro order covers every company we can verify there.

Companies

$300

1,004+ companies with a phone

  • Nationwide, or narrowed to your states or metros
  • Company phone; website and general email where published
  • Location and the fields on this page
  • CSV emailed within 24-48 hours

Named decision-makers

$600

596+ named decision-makers

  • The CEO / founder, head of R&D / CSO, VP clinical operations, business development, manufacturing / CMC lead at each company, by name
  • 596+ with a verified email; company phone for the rest
  • Each person checked as current in the role
  • Companies we cannot confirm are left out, never guessed

Decision-makers + signal

$1,200

Decision-makers plus the signal

  • Everything in the researched list
  • Companies that started a new clinical trial in the last 12 months (ClinicalTrials.gov)
  • Researched from public records and each company's own pages
  • The rows most worth calling first, marked

One-time purchase. Card payment with bank authentication. Built to order and emailed as a CSV within 24-48 hours. If a list comes in under the floor we state, we tell you before delivery and refund the difference or widen the scope. Any email that bounces within 30 days is replaced or refunded.

Check the quality first: free sample of 25 rows

The sample is the real thing: 25 rows with a named decision-maker, verified email and phone, checked by hand. It downloads as a CSV.

The market, sized in November 2026

5,291

Drug and biologic trial sponsors since 2021, worldwide

2,690

In scope after exclusions (estimate)

1,004+

In a 24-48-hour national file

596+

Named decision-makers in that file

596+

Verified emails in that file

The market figure counts every company that was lead industry sponsor of a drug or biologic trial on ClinicalTrials.gov started since January 2021 or still open, worldwide: 5,291 after merging name variants, pulled November 16, 2026. The in-scope count applies the share of US-headquartered developers found in a random 80 sponsors checked by hand, and adds US companies with no recent trial from verified business contact records, measured on a random 30.

Who is in it
US biotechnology and pharmaceutical companies (drug, biologic, cell and gene therapy developers, from venture-backed startups to public companies), with parent companies flagged; with the CEO, R&D, clinical operations, business development or manufacturing lead identified
Left out on purpose
medical device companies (own page), contract research and manufacturing organizations as such (unless they develop their own drugs), pharmacies, distributors
The person on each row
CEO / founder, head of R&D / CSO, VP clinical operations, business development, manufacturing / CMC lead
Can be narrowed by
state, region or city, metro, therapeutic area, clinical stage, public or private, headcount, new trial in the last 12 months

Companies on the list

10 of about 2,690, as examples. People and contact details are in the file, not on this page.

CompanyCityStateType
Phathom PharmaceuticalsFlorham ParkNJPublic commercial-stage GI drug company
ARS PharmaceuticalsSan DiegoCAPublic company, epinephrine nasal spray
Cartesian TherapeuticsGaithersburgMDPublic clinical-stage mRNA cell therapy developer
Palleon PharmaceuticalsWalthamMAVenture-backed glyco-immunology biotech, Phase 2
QOL MedicalVero BeachFLPrivate rare-disease enzyme therapy maker
Crestone, Inc.BoulderCOPrivate clinical-stage antibiotic developer (C. difficile)
PronirasSeattleWAClinical-stage small-molecule developer
Airway TherapeuticsAtlantaGAClinical-stage biologic developer for lung injury
Sapience TherapeuticsTarrytownNYVenture-backed clinical-stage oncology company
Genzada PharmaceuticalsHutchinsonKSSmall oncology drug discovery company

How this list is built

The list starts from public trial registrations, not a marketing database.

  1. Trial sponsors: every industry lead sponsor of an interventional drug, biologic, gene or combination-product study on ClinicalTrials.gov started since 2021 or still open, with name variants and country units merged.
  2. Headquarters: trial records list sites, not headquarters, so each company is placed by its own website or verified business contact records. In a random 80 sponsors the exclusions were foreign headquarters, units absorbed into a parent such as Merck or GSK, device makers and supplement firms.
  3. No-trial developers: US biotech and pharma companies from verified business contact records with no recent trial; CROs, consultancies, pharmacies, wholesalers and diagnostics firms are removed by hand (18 of a random 30).
  4. Decision-maker: CEO or founder, CSO or head of R&D, clinical development or operations, business development and CMC leads, from company sites and verified business contact records. Pattern-built emails are left out.
  5. What the 48-hour file contains: 1,000+ companies with a company phone (about 810 clinical-stage, 190+ without a recent trial), 590+ with a named decision-maker and verified email, each flagged public, private or parent-owned.
  • ClinicalTrials.gov (National Library of Medicine): Lead sponsor, study start and first-posted dates, phase, intervention type, conditions and site countries for every registered trial
  • Company websites: Headquarters address, pipeline and stage, leadership and parent company
  • Verified business contact records: US-headquartered biotech and pharma companies, decision-makers by title, verified emails and company phones
  • Nasdaq Trader symbol directory: Names of companies listed on Nasdaq, NYSE and other US exchanges, used for the public-company flag
  • Census County Business Patterns 2023: 2,905 pharmaceutical and medicine manufacturing establishments (NAICS 3254) and 5,670 biotechnology R&D establishments (NAICS 541714)

Who buys this list, and how to use it

CROs and CDMOs, lab equipment and reagent suppliers, clinical trial software vendors and site networks, patient recruitment firms, regulatory consultants, biotech recruiters, life-science landlords, and investors and bankers buy this list.

  • Titles: CEO or founder; CSO or head of R&D; CMO or VP clinical development; VP clinical operations; chief business officer; VP CMC or technical operations.
  • Timing: the J.P. Morgan Healthcare Conference in January sets the year's financing and partnering tone; AACR, ASGCT, ASCO, BIO and INTERPHEX fill the spring. Next year's studies are planned in Q3 and Q4.
  • Response: expect 1-2% replies to a general offer, more when it is tied to a phase, modality or indication. Large pharma routes vendors to procurement.
  • Tip: a company that has just started a trial or closed a round outsources within weeks, so pair the new-trial flag with phase and indication.

How every order is compiled

This is not an export from a stored contact database. Your file is compiled from scratch in the 24-48 hours after you order, for the whole country or just your territory, using the same method that built the free sample.

Built for your order, never reused

Reply to your order receipt with the cut you want: your states or metros, which companies to keep or leave out (any of the filters under “Can be narrowed by”), the titles to name, and how recent the signal should be. We build the file to that brief, at the same price. There is no master file on a shelf: each file is compiled for one buyer, and no buyer's file is ever reused for another order.

  1. 1
    Rebuilt from the original sources on the day of your order. We don't keep this list on a shelf. When you order, we go back to these sources and run the search again across every state, or only your territory:
    • ClinicalTrials.gov (National Library of Medicine)
    • Company websites
    • Verified business contact records
    • Nasdaq Trader symbol directory
    • Each company's own website
    New openings are picked up, companies that closed or changed hands drop out, and the file is dated the day it is built.
  2. 2
    Every company read on its own website. We open each company's website and read its home, services and about pages. A company stays in the file only if those pages show it fits this page's definition; a matching industry code or a keyword in its name is never enough on its own. Everything under "Left out on purpose" is removed.
  3. 3
    Ownership and status checked. We search each company's name with terms like "acquired", "joins", "part of" and "portfolio company", because a website often still reads independent months after a sale. That keeps each row's owner current, removes companies of a kind this page leaves out (such as hospital-owned practices) and catches any that have closed.
  4. 4
    Duplicates merged. Rows are matched on phone number, website domain, street address and name, so branches, trade names and duplicate registry records collapse into one company.
  5. 5
    The right person, confirmed current. For the researched file we look for the CEO / founder, head of R&D / CSO, VP clinical operations, business development, manufacturing / CMC lead on the company's own team or about page, in public filings (such as the official named on a registry or license record) and in verified business contact records. Each person must be shown with the company today, on its own site or a second current source. A match to someone with the same name at a different company is thrown out.
  6. 6
    Emails verified at build time. Each named email must come back verified when your file is built, sit on the company's own domain, and that domain must have a working mail server (we check its MX record). We never guess an address from a name pattern. Shared inboxes like info@ or office@ go in a separate general-email column, never next to a person's name.
  7. 7
    Phones that reach the company. Every phone number is compared with the one on the company's own website or business listing. Registry and license numbers are often years old, so when they disagree, the company's current number wins.
  8. 8
    Checked row by row before delivery. An automated check rejects the file if it has duplicate companies, rows without a phone, or cells a spreadsheet would turn into dates. Then we open 20 random rows (100 on large files) and check each one against its source. The CSV comes with a note listing what we checked and what we removed. If the file comes in under the numbers on this page, we tell you before delivery and refund the difference.

Read the full method: your ideal customer, plus the signal that says why now →

Frequently asked questions

Are big pharma companies and their subsidiaries included?

Yes. US-headquartered drug companies of every size are in, from Pfizer, Lilly and Merck to two-person startups, and each row is flagged public, private or owned by a parent. Acquired biotechs that now run inside a parent, such as units folded into Merck or GSK, are merged into that parent. US arms of foreign-headquartered groups are left out unless you ask for them.

What counts as clinical stage, and how are preclinical companies found?

Clinical stage means the company sponsored a drug or biologic trial on ClinicalTrials.gov that started since 2021 or is still open: about 1,590 US companies. Preclinical companies have no registry, so they come from verified business contact records and are checked by hand; in a random 30 drug-named companies, 9 were real developers and 18 were CROs, consultancies or other services.

How is the new-trial signal built?

It flags companies, not trials: each company that is lead sponsor of a drug or biologic study whose actual start date on ClinicalTrials.gov falls in the last 12 months. 1,286 sponsors worldwide qualify, and 220+ are confirmed US-headquartered developers at the cautious end. In 8 hand-checked records, every study was the sponsor's own and newly started.

Are device makers, CROs and contract manufacturers included?

Not as such. Device and diagnostics companies are on the medical device manufacturers and independent clinical labs lists. CROs and contract manufacturers are left out unless they develop their own drugs. Census counts 2,905 pharmaceutical and medicine plants, which mix makers of every kind, so that figure is context only.

How many biotech and pharma companies will my file have?

A national order delivers at least 1,004 companies with a company phone (website and general email where published), and the researched file names a CEO / founder, head of R&D / CSO, VP clinical operations, business development, manufacturing / CMC lead at 596 or more of them (596+ with a verified email), within 24-48 hours. The market itself is about 2,690 companies, sized November 2026; a narrowed order covers every one we can verify in that area. If a file comes in under these numbers, we tell you before delivery and refund the difference.

Is this an export from a contact database?

No. Each file is compiled after you order, in 24-48 hours: we pull the sources behind this page again, check every company on its own website, merge duplicates, confirm each named person is in the role today, verify every email at build time and hand-check random rows before delivery. A stored database goes stale as companies open, close and change hands; building at order time avoids that.

Is my file reused or sold to anyone else?

No. Every file is built from scratch for one order, to that buyer's filters: their territory, which companies to keep or leave out, the titles to name and how recent the signal should be. We don't keep a master file to resell, and no buyer's file is ever reused for another order. Two buyers who order the same market each get their own fresh build, so some companies will overlap, but nobody receives someone else's file.

What if some emails bounce?

Every email is verified when the list is built. If any address hard-bounces within 30 days of delivery, reply to your delivery email with the bounced addresses. We re-check each one and replace it with a working address at the same company, or refund that share of your order if we can't. If more than 10% of a file's emails bounce, you can have your money back instead.

How fast is it delivered?

Within 24-48 hours of payment, as a CSV emailed to you, with a permanent download link.

Can it be narrowed to my territory?

Yes. Every list can be narrowed by state, region or city, and this one also by metro, therapeutic area, clinical stage, public or private, headcount, new trial in the last 12 months. Reply to your order receipt with the cut you want; the price stays the same.

Where does the data come from?

Public sources: ClinicalTrials.gov (National Library of Medicine); Company websites; Verified business contact records; Nasdaq Trader symbol directory; Census County Business Patterns 2023. Every row is checked against the company's own website before delivery, emails are verified, and anything we cannot confirm is left out rather than guessed.

Related lists

Trade shows where these companies exhibit